Evidence mapPaperPMID 40076782Full record

ReviewInternational journal of molecular sciences2025

Vitamin D and Type 2 Diabetes Mellitus: Molecular Mechanisms and Clinical Implications-A Narrative Review.

Héctor Fuentes-Barría, Raúl Aguilera-Eguía, Cherie Flores-Fernández, Lissé Angarita-Davila, Diana Rojas-Gómez, Miguel Alarcón-Rivera, Olga López-Soto, Juan Maureira-Sánchez

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Héctor Fuentes-BarríaVicerrectoría de Investigación e Innovación, Universidad Arturo Prat, Iquique 1100000, Chile.ORCID 0000-0003-0774-0848
Raúl Aguilera-EguíaDepartamento de Salud Pública, Facultad de Medicina, Universidad Católica de la Santísima Concepción, Concepción 3349001, Chile.
Cherie Flores-FernándezDepartamento de Gestión de la Información, Universidad Tecnológica Metropolitana, Santiago 7550000, Chile.
Lissé Angarita-DavilaEscuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Concepción 3349001, Chile.ORCID 0000-0001-7860-5112
Diana Rojas-GómezEscuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Santiago 7550000, Chile.ORCID 0000-0002-6956-6315
Miguel Alarcón-RiveraEscuela de Ciencias del Deporte y Actividad Física, Facultad de Salud, Universidad Santo Tomás, Talca 3460000, Chile.ORCID 0000-0001-8341-5567
Olga López-SotoFacultad de Salud, Universidad Autónoma de Manizales, Manizales 170017, Colombia.
Juan Maureira-SánchezFacultad de Educación, Universidad Central de Chile, Santiago 7550000, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D has been widely studied for its implications on type 2 diabetes mellitus, a chronic condition characterized by insulin resistance, inflammation, and metabolic dysfunction. This review explores the molecular mechanisms underpinning vitamin D's effects on glucose metabolism, inflammation, and adipogenesis, while assessing its potential clinical applications in type 2 diabetes. In its 1,25-dihydroxyvitamin D3 form, vitamin D modulates various metabolic processes, affecting proinflammatory cytokines and activating the AMPK pathway, inhibiting mTOR signaling, and promoting adipocyte differentiation. These effects enhance insulin sensitivity and reduce chronic inflammation, key contributors to metabolic dysfunction. In this context, the progression of prediabetes has been linked to vitamin D, which limits pathological progression and increases the likelihood of restoring a normal metabolic state, crucial in diabetes progression. Moreover, vitamin D has been reported to reduce the likelihood of developing diabetes by 15%, particularly in doses higher than the traditional recommendations for bone health. Despite promising evidence, discrepancies in study designs, serum vitamin D measurements, and population-specific factors highlight the need for standardized methodologies and personalized approaches. In conclusion, vitamin D has complementary therapeutic potential in treating type 2 diabetes, revealing gaps in research, such as optimal dosing and long-term effects across populations. Future studies should integrate molecular insights into clinical practice to optimize vitamin D's impact on metabolic health.

Indexed as

Diabetes Mellitus, Type 2Vitamin DAdipogenesisAnimalsHumansInflammationInsulin ResistanceSignal TransductionVitamin Dmolecular biologytype 2 diabetes mellitusvitamin D

Identifiers

PMID40076782
PMCPMC11900948

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.